flu drugs keep biota healthy - page 46 fin rev, page-4

Sorry MW I am not a regular subscriber of AFR.
I only came across the article after buying a copy today.

Key points:

1. Analyst speculating about licensing partners for Laninamivir for North America and Europe. Obvious partner is GSK but some anaylysts tipped Sanofi-Aventis.
2. BTA expects registration of the product 1Q 2010 in Japan.
3. 1 dose of Laninamivir = 2 doses x 5 days of Tamiflu.
4. BTA to return $20m to investors.
5. Analyst expects increased production of Relenza by GSK to deliver $108.7m in fiscal 2010.

A very positive article.